Important Information for Investors: Rosen Law Firm Reminds Buyers of Zynex, Inc. (ZYXI) Securities of Upcoming Deadline
NEW YORK, April 03, 2025 – Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023, and March 11, 2025, both dates inclusive (the “Class Period”), of the upcoming May 19, 2025 lead plaintiff deadline.
Background:
Zynex, Inc. is a Colorado-based healthcare technology company that designs, manufactures, and markets medical devices and healthcare IT services. The Company’s products include transcutaneous electrical nerve stimulation (TENS) devices for pain management, rehabilitation devices, and electrotherapy devices.
Securities Class Action:
The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (1) Zynex’s revenue growth was primarily due to sales of its TENS devices, which were not sustainable due to reimbursement issues; (2) Zynex’s financial statements for the quarters ending December 31, 2022, and March 31, 2023, contained material misstatements; and (3) as a result, defendants’ statements about Zynex’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Lead Plaintiff Deadline:
The lead plaintiff is the petitioner in a securities class action who proposes to act on behalf of all other class members in directing the litigation. In order to be appointed lead plaintiff, the claimant must meet certain legal requirements and must demonstrate, at the time the lead plaintiff motion is filed, that the amount in controversy exceeds the amount of the minimum requirements for class action certification. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025.
Effect on Individual Investors:
If you purchased Zynex securities during the Class Period, you may be entitled to compensation without incurring litigation costs or attorneys’ fees. The lead plaintiff will seek to appoint a law firm who will represent the class in the action. If appointed, the lead plaintiff and the class representative will work with the appointed law firm regarding the filing and managing of the lawsuit. You do not need to take any action at this time to be a member of the class. If you wish to learn more about the class action, go to
Effect on the World:
The securities class action against Zynex is one of many lawsuits that have been filed against publicly traded companies in recent years. These lawsuits, often referred to as securities fraud class actions, allege that the companies and their executives made false or misleading statements to investors, resulting in artificially inflated stock prices. If the plaintiffs in these lawsuits are successful, they can recover substantial damages for the harm suffered by investors. The outcome of these lawsuits can also have broader implications for the business community, as they can lead to increased scrutiny of corporate disclosures and governance practices.
Conclusion:
If you purchased Zynex securities between March 13, 2023, and March 11, 2025, you may be entitled to compensation as a result of the company’s alleged securities fraud. The lead plaintiff deadline for this class action is May 19, 2025. If you wish to serve as lead plaintiff, you must file a motion with the Court by that date. The outcome of this lawsuit, and others like it, can have significant implications for both individual investors and the business community as a whole.
- Rosen Law Firm reminds purchasers of Zynex securities between March 13, 2023, and March 11, 2025, of the May 19, 2025 lead plaintiff deadline.
- The complaint alleges that Zynex made false or misleading statements about its revenue growth and financial statements.
- Individual investors who purchased Zynex securities during the Class Period may be entitled to compensation.
- The lead plaintiff deadline for this class action is May 19, 2025.
- The outcome of this lawsuit, and others like it, can have significant implications for both individual investors and the business community as a whole.
